Akrikhin, KhFK

History

2023

Structural Changes and Assignments

Akrikhin continues to strengthen its internal organization and focus on the development of key business segments. To this end, the company has undergone personnel changes: a commercial director and vice president for the direction of generic drugs have been appointed. The company announced this on February 16, 2023.

The transformation of the business realities of the pharmaceutical market, the active development of the commercial sector and sales channels, in particular, e-commerce, require the implementation of the most advanced practices and management solutions. At the end of 2022, in order to implement AKRIKHIN's strategic plans, a commercial director was appointed - Alexander Sokolov. In this position, he reports to the president of the company Denis Chetverikov.

Another appointment in the company is due to the fact that in 2023 the direction of generic drugs "AKRIKHIN" is allocated to an independent business unit - the sales and marketing service for generic drugs. Thanks to such changes, the company strengthens its focus on the business of generic drugs - the INN-Akrikhin portfolio, creates additional resources for their promotion of all sales channels, including pharmacy chains, e-commerce and government supplies, as well as opportunities to increase the production of portfolio drugs at the local production site in Staraya Kupavna.

The business unit was headed by Lidia Choborovskaya, Vice President for Generic Drugs, with direct subordination to the President of the company Denis Chetverikov.

In the product portfolio - more than 200 drugs

As of February 2023, the company's product portfolio includes more than 200 drugs, about 45% of which are included in the list of vital and essential drugs (vital and essential drugs). The drugs belong to the main pharmacotherapeutic directions - dermatology, cardiology, pediatrics, neurology, gynecology, pulmonology, endocrinology, gastroenterology, rheumatology, ophthalmology, etc. - and are produced in full compliance with GMP standards.

2019: Launch of Venolife DUO venotonizing drug

On April 24, 2019, it became known that AKRIKHIN presented the venotonizing drug Venolife DUO of its own design. The drug in the form of tablets enters the market from the Venolife brand. Read more here.

2018: Alexandra Lukashova appointed vice president of marketing and sales

On September 19, 2018, it became known that Alexandra Lukashova took over as Vice President for Marketing and Sales of Branded and Generic Drugs.

She will direct two business units: Prescription Drug Sales and Marketing and Generic Drug Sales and Marketing.